Josef Straub

Tepotinib in Non–Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping Mutations

Paul K. Paik, Enriqueta Felip, Rémi Veillon et al. · New England Journal of Medicine · 2020 · 854 citations · Full text

Medicine, Oncology, Pharmacology +15

Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial

Yi‐Long Wu, Ying Cheng, Jianying Zhou et al. · The Lancet Respiratory Medicine · 2020 · 258 citations

Medicine, Oncology, Pharmacology +17

Validation of Real-Time Methylation-Specific PCR to Determine O6-Methylguanine-DNA Methyltransferase Gene Promoter Methylation in Glioma

Ilse Vlassenbroeck, Stèphane Califice, Annie‐Claire Diserens et al. · Journal of Molecular Diagnostics · 2008 · 200 citations · Full text

Medicine, Genetics, Molecular Biology +14

Identification and Validation of the Methylated TWIST1 and NID2 Genes through Real-Time Methylation-Specific Polymerase Chain Reaction Assays for the Noninvasive Detection of Primary Bladder Cancer in Urine Samples

Isabelle Renard, Steven Joniau, Ben Van Cleynenbreugel et al. · European Urology · 2009 · 165 citations

Medicine, Molecular Biology, Oncology +16

<i>MGMT</i> Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials

Monika E. Hegi, Els Genbrugge, Thierry Gorlia et al. · Clinical Cancer Research · 2018 · 149 citations · Full text

Medicine, Oncology, Pharmacology +17